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PURPOSE. We analyzed the preoperative conjunctival goblet cell density (GCD), MUC5AC, and
HLA-DR in glaucomatous patients undergoing trabeculectomy, using laser scanning confocal
microscopy (LSCM) and impression cytology (IC).
METHODS. We enrolled 57 patients undergoing trabeculectomy. At baseline LSCM and IC were
performed at the site planned for surgery; LSCM was repeated after 12 months at the bleb site.
The main outcomes were: GCD, mean microcyst density (MMD) and area (MMA) at LSCM,
MUC5AC, and HLA-DR positivity at IC, and IOP. The relationships between baseline GCD, and
12-month IOP, MMD, and MMA were analyzed.
RESULTS. Trabeculectomy was successful in 39 patients (complete success in 27, Group 1;
qualified in 12, Group 2), and unsuccessful in 18 (Group 3). At baseline IOP (mm Hg) was
27.2 6 3.12, 27.5 6 2.23, and 27.7 6 1.90 in Groups 1 to 3, respectively; GCD and MUC5AC
positivity were higher in Group 1 compared to Groups 2 and 3 (P < 0.05); HLA-DR, MMD, and
MMAwere not significantly different among the groups. At 12 months, IOP reduced by 45.3%,
35.4%, and 12.8% in Groups 1 to 3, respectively. Goblet cell density did not change in Group
1, whereas it was reduced in Groups 2 and 3 (P < 0.05), with values lower in Group 3. Mean
microcyst density and MMA increased in Groups 1 and 2 (P < 0.05), with values higher in
Group 1 (P < 0.05). Baseline GCD positively correlated with 12-month IOP reduction (P <
0.001, r ¼ 0.641), MMD (P < 0.05, r ¼ 0.454), and MMA (P < 0.001, r ¼ 0.541).
CONCLUSIONS. Goblet cells positively affect the filtration ability after trabeculectomy; therefore,
preoperative GCD could be considered as a potential in vivo biomarker of surgical success.
Keywords: conjunctival goblet cells, MUC5AC, HLA-DR, trabeculectomy, in vivo confocal
microscopy, impression cytology
Filtration surgery is one of the most effective surgicalprocedure for lowering IOP in patients with medically
uncontrolled glaucoma.1,2 Successful surgery leads to an
elevation of the conjunctiva at the surgical site, which is
referred to as a filtering bleb. The aqueous humor (AH) flows
into bleb spaces and then is removed by several routes, such as
the transconjunctival routes.3–5
The transconjunctival pathway was documented after intra-
cameral injection of fluorescein in patients undergoing
trabeculectomy.6 Laser scanning confocal microscopy (LSCM)
confirmed the existence of this pathway in vivo,7 also in
patients who did not undergo previous surgery (as the terminal
portion of the uveoscleral AH outflow).8 In functioning blebs
LSCM observed optically clear microcysts within the conjunc-
tival epithelium, which were expressions of AH percolation
toward the ocular surface; conversely, in failed blebs these
structures were rare or absent. Thus, microcysts were
interpreted as transcellular vesicles transporting AH through
the bleb wall. Amar et al.9 clarified the nature of epithelial
microcysts (EM): based on the topographic correspondence
between MUC5AC-postive cells and epithelial empty spaces in
functioning blebs, the authors proposed that EM corresponded
to goblet cells (GC) containing AH. Therefore, the trans-
conjunctival AH pathway through the bleb wall epithelium was
hypothesized to occur at the level of GC.
Goblet cell density (GCD) and MUC5AC, the main mucin
product of GC, were found significantly overexpressed in
successful compared to failed surgeries: histology and confocal
microscopy showed that a higher postoperative GCDwas related
to a good IOP control and a higher success rate.9–11 On this basis,
the preservation of GC seems critical because the final filtering
ability of a bleb could depend on the number of GC available
before, and surviving surgery. The aim of the present study was to
correlate the preoperative conjunctival GCD and MUC5AC
positivity, using in vivo LSCM and impression cytology (IC), with
the 12-month success in patients undergoing filtration surgery.
METHODS
Patient Selection
This was a 12-month, prospective, interventional, case-control
study. The patients were treated in accordance with the criteria
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of the Declaration of Helsinki. Our institutional review board
(Department of Medicine and Ageing Science, G. d’Annunzio
University of Chieti-Pescara, Chieti, Italy) approved the project.
We enrolled 57 consecutive Caucasian patients (57 eyes) with
uncontrolled open angle glaucoma scheduled to undergo MMC
augmented trabeculectomy.
A total of 15 consecutive age- and sex-matched healthy
subjects were used as controls. Written informed consent was
obtained from all subjects before enrollment, after explanation
of the nature and possible consequences of the study.
Inclusion criteria for patients who were surgical candidates
were the following: diagnosis of open angle glaucoma
(including primary open-angle, pseudoexfoliative, and pigmen-
tary glaucoma), uncontrolled IOP (>20 mm Hg, mean of three
measurements at 9 AM, 12 PM, and 4 PM) under maximal
tolerated medical therapy (MTMT; unmodified during the last 3
months), progression of glaucomatous damage confirmed on
three consecutive visual fields (VF; 30-2 test, full-threshold,
Humphrey field analyzer II 750; Carl Zeiss Meditec, Inc.,
Dublin, CA, USA). Maximum tolerated medical therapy
required the use of all available classes of IOP lowering eye-
drops and oral acetazolamide, without significant side effects.
Visual field damage progression was assessed with the trend-
based analysis of the HFA Guided Progression Analysis
software: when the magnitude of visual field index slope was
worse than 1% per year with a P value  0.05, the progression
was considered clinically significant.
Subjects were included if they had histories of laser
trabeculoplasty or cataract surgery, performed at least 6
months before enrollment.
If both eyes were eligible, the eye with the higher IOP level
or the more advanced stage of glaucoma (according to the
glaucoma staging system 2 [GSS2]),12 was included in the study.
Exclusion criteria were diagnosis of angle-closure, normal
tension, neovascular or uveitic glaucoma; history of previous
incisional glaucoma surgery, penetrating keratoplasty, extra-
capsular cataract extraction, cataract extraction planned at the
time of filtering surgery or within 12 months thereafter; history
of ocular diseases in the operated eye other than glaucoma and
cataract; systemic or topical therapies in the last 6 months that
could have modified the AH hydrodynamics or the ocular
surfacel contact lens wear; and pregnancy. Patients who
received medical, laser, or surgical therapy, or who had ocular
surface diseases during the follow-up were excluded from the
study. Surgery was considered successful when at least 30%
reduction from preoperative IOP was obtained at 12 months.
Eyes that met the above criteria and were not on supplemental
anti-glaucoma medical therapy were defined as achieving a
complete success, whereas eyes that met the criteria with
supplemental medical therapy were defined as achiecing a
qualified success.13
Inclusion criteria for controls were best-corrected visual
acuity greater than or equal to 8/10, mean IOP lower than 18
mm Hg, absence of glaucomatous optic neuropathy, and a
normal visual field examination. None of the healthy subjects
had either a history of topical or systemic therapy nor were
they affected with any ocular or systemic diseases in the last 6
months. Pregnant women and contact lens wearers were
excluded. Both eyes were evaluated, but one eye per control
subject was chosen randomly (using a computer generated
random number list) for the statistical analysis.
Baseline evaluations included measurement of visual acuity
and IOP (Goldmann applanation tonometry; mean of three
measurements), slit-lamp anterior segment and fundus exam-
ination, visual field, and LSCM, and IC.
Patients underwent a weekly follow-up in the first month
after surgery, and monthly afterwards; baseline and 12-month
data were considered for the statistical analysis.
LSCM of the Conjunctiva
We performed LSCM to evaluate GC density and EM density
and area. For the examination of presumed GC and microcysts,
we adopted a definition and reference images of GC and EM
consistently with those reported in the literature.7–9,14–19
Presumed GC were defined as large to giant oval-shaped
cells with central or peripherally displaced hyporeflective
nuclei, hyperreflective and two/three times larger than the
surrounding epithelial cells, dispersed within the epithelium or
crowded in groups. Microcysts were defined as round- or oval-
shaped extracellular structures, optically clear because of the
low internal reflectivity, dispersed or clustered within the
epithelium, occasionally containing amorphous material or
inflammatory cells.
For days before filtration surgery the upper bulbar
conjunctiva was examined using a digital confocal laser-
scanning microscope (HRT III Rostok Cornea Module [RCM];
Heidelberg Engineering, Heidelberg, Germany). The technical
characteristics of this instrument and the details of conjunc-
tival examination have been described previously.7–9
The confocal laser-scanning device was equipped with a
water immersion objective (633/N.A. 0.95 W; Carl Zeiss
Meditec, Inc.) and permitted an automatic z-scan determina-
tion of depth of focus within the conjunctiva. Thus, high-
contrast digital images of epithelium (15–30 lm of depth; 2
mm from the limbus at the site of the planned surgery in
downward gaze) with a field of view of 400 3 400 lm were
acquired. The automatic brightness mode was selected during
examination.
To analyze the same conjunctival portion with LSCM and IC,
a 53 5 mm area of the upper bulbar conjunctiva, centered at
12 o’clock meridian of the limbus, was marked using
methylene blue. In eyes that were schedules for surgery, this
area corresponded to the site where a bleb would be
positioned. Particular attention was adopted in maintaining
the RCM (and the strip for IC afterwards) within the marked
area.
We acquired 48 images for each eye, and 12 randomly
selected high-quality images without motion blur or compres-
sion lines were selected for the analysis. The Cell Count
Software in manual mode was used to determine the number
of GC and EM.
The surface area of EM was calculated using ImageJ
software (http://imagej.nih. gov/ij/; provided in the public
domain by the National Institutes of Health [NIH], Bethesda,
MD, USA).
Eyes that underwent surgery received unpreserved topical
steroids for 4 weeks (unpreserved dexamethasone 0.15% eye-
drops four times a day for 2 weeks and three times daily for the
following 2 weeks) and topical antibiotic for the initial 2 weeks
(unpreserved levofloxacin 5 mg/mL 4-fold daily). Postoperative
procedures, such as subconjunctival injections of 5-fluoroura-
cil (5-FU), laser suture lysis, and bleb needling, were performed
when needed. Laseer scanning confocal microscopy was
repeated after 12 months at the bleb site to evaluate GCD,
mean microcyst density (MMD), and mean microcyst area
(MMA).
A single operator (LB) performed all confocal examinations
and selected the images, which were evaluated by a second
operator (VF). Operator VF and operator LB during the image
selection were masked for the subject history and for grouping.
Confocal session lasted less than 5 minutes, and none of the
patients reported visual symptoms and complications related
to the procedure.
Two masked investigators (VF, investigator 1; LB, investiga-
tor 2) independently calculated the GCD, MMD, and MMA to
assess the interobserver variability.
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IC of the Conjunctiva
Impression cytology was performed to evaluate the expression
of HLA-DR and MUC5AC in the conjunctival epithelium, at the
site planned for surgery, within the marked area, at baseline.
Since IC is a more invasive procedure with respect to IVCM,
the examination was not repeated after 12 months to avoid any
potential bleb damage. Impression cytology sampling was
performed from 36 to 48 hours after confocal microscopy to
avoid misinterpretation due to the mechanical pressure during
execution of the LSCM. After instillation of 1 drop of 0.4%
oxybuprocaine, a strip (previously cut in 5 3 5 mm to match
the marked area) was applied on the upper bulbar conjunctiva
(with the eye in downward gaze), and then pressed gently by a
glass rod to obtain a cytological biopsy. Impression cytology
samples were collected using Millicell-CM 0.4 mL (12 mm of
diameter; Millipore, Bedford, MA, USA) membrane. The
Millicell membranes were hydrated with distilled water and
placed in 80% alcohol for 2 minutes. The membranes were
washed in distilled water and PBS was added for 2 minutes,
followed by 2 washes with Wash Buffer (Dako, Glostrup,
Denmark) of 2 minutes each. Then, Ribonuclease A (Sigma-
Aldrich Corp., St. Louis, MO, USA) diluted 1:290 in PBS was
incubated for 20 minutes at room temperature. The specimens
were washed and PBS-BSA 1% was added for 1 hour at room
temperature. Finally, each membrane was cut in two pieces
and incubated overnight at 48C with MUC5C or HLADR diluted
1:50 (Dako).
Samples were washed and anti-mouse IgG1 Alexa fluor 488
(Invitrogen, San Giuliano Milanese, Italy) diluted 1:200 and
propidium iodide at 1:150 were added and incubated for 1
hour at room temperature. Membranes were mounted with a
drop of Fluorescent Mounting Medium (Dako) and Zeiss
Confocal LSM 510 (Carl Zeiss MicroImaging GmbH, Vertrieb,
Germany) was used to visualize the cells. Five different fields
for each IC sample were evaluated. Positive (red nucleus and
green cytoplasm) and negative (red nucleus) cells were
counted. Minor irregularities that may have been present after
cutting the membranes were normalized by reporting the
percentage of positive cells for HLA-DR or MUC5AC.
Two independent observers (CC and AM) masked to the
details of the staining technique performed evaluations of IC
specimens. Digital images of representative areas were taken.
None of the patients reported complications related to IC
sampling. Healthy control subjects underwent IC with the
same modality.
The primary outcomes were the baseline GCD at LSCM and
12-month IOP; the secondary outcomes were the baseline
positivity of MUC5AC and HLA-DR at IC, and 12-month GCD,
MMD, and MMA at LSCM.
The correlations between GCD and MUC5AC, GCD, and
HLA-DR, and MUC5AC and HLA-DR at baseline were evaluated;
the correlations between baselines GCD, MUC5AC, and HLADR
and 12-month IOP, MMD, and MMA also were evaluated.
Statistical Analysis
Analysis was performed by SPSS Advanced Statistical TM 13.0
Software and SPSS Sample Power Software (2005; SPSS, Inc.,
Chicago, IL, USA). Student’s t-test and v2 test were used to
evaluate age and sex differences between groups. A 1-way
ANOVA with post hoc Tukey for multi-comparison was used to
assess differences among groups. ANOVA repeated measures,
was used to assess differences between baseline and 12
months.
The sample size was established calculating a rate
difference of at least 50% between groups for v2 or Fisher’s
exact tests and of 52% for Mann-Whitney U and Wilcoxon tests,
for a power of 80%.
Correlations among the variables were determined using a
nonparametric measure by the Spearman’s index. A P value
< 0.05 was considered statistically significant. The values
obtained by investigator 1 (VF) were used for the statistical
analysis, and the values obtained by investigator 2 (LB) were
used to assess the interobserver agreement.
RESULTS
The demographic and clinical data of the enrolled patients are
shown in Table 1. All patients completed the study and no
major intra- or postoperative complications occurred. No
patient received steroids before surgery or had ocular surface
diseases during follow-up.
Clinical Data
The surgical procedure was successful in 39 patients (68.4%),
with complete (Group 1) and qualified (Group 2) success in 27
and 12 patients (69.2% and 30.7%), respectively; surgery was
unsuccessful (Group 3) in 18 patients (31.6%).
Baseline IOP was not significantly different between
glaucoma groups, but was significantly lower in controls; after
12 months, IOP significantly reduced in Groups 1 and 2 (P <
0.05) without differences between Groups, whereas it did not
change in Group 3 and controls. The 12-month IOP reduction
was 45.3% and 35.4% in Groups 1 and 2, respectively, and
12.8% in Group 3. Table 2 reports the baseline therapy of the
groups.
Laser Scanning Conformal Microscopy
Baseline and 12-month LSCM parameters are reported in Table
3. Goblet cells and EM were observed in all glaucoma patients
and in controls, and were morphologically similar to those
described previously.7–9,15–17 Goblet cells were readily ob-
served within the epithelium at 20 lm of depth, and appeared
as large cells, hyperreflective, and oval-shaped with hypore-
flective nuclei, larger than the surrounding epithelial non-
goblet cells, crowded in groups or dispersed within the
epithelium (Figs. 1–3A).
Microcysts appeared as round- or oval-shaped extracellular
structures, ranging from 10 to 90 lm in size, with an optically
clear aspect due to the low internal reflectivity, located at the
intermediate layer of the epithelium (10–30 lm in depth Figs.
1–3C, 3F). Occasionally, they were filled with amorphous
material or mononucleate hyperreflective elements probably
corresponding to inflammatory cells.
At baseline GCD was significantly higher in Group 1
compared to Groups 2 and 3 (P < 0.05), but significantly
lower compared to controls (P < 0.001; Figs. 1–3A). Mean
microcyst density and MMA were not significantly different
between glaucoma groups, and were significantly lower in
controls (P < 0.05; Figs. 1–3C).
After 12 months, GCD did not significantly change in Group
1, whereas it was significantly reduced in Groups 2 and 3 (P <
0.05), with values lower in Group 3 (Figs. 1–3E). Mean
microcyst density and MMA significantly increased in Groups 1
and 2 (P < 0.05), with values significantly higher in Group 1 (P
< 0.05; Figs. 1–3F). Mean microcyst density and MMA
presented a 7- and an 8-fold increase in Group 1, respectively,
and a 3-fold increase in Group 2. Microcyst parameters did not
significantly change in Group 3.
For the purpose of determining interobserver variability, all
three groups of patients and healthy controls were combined.
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The baseline GCD, MMD, and MMA estimated by investigator 1
(VF) were not significantly different (P > 0.05) from that
estimated by the investigator 2 (LB) (Table 4).
Impression Cytology
Baseline IC results are reported in Table 5. Human leukocyte
antigen DR (HLA-DR) positivity did not show significant
differences between groups, but was significantly lower in
controls (P < 0.001; Figs. 1–3D). Positivity for MUC5AC was
significantly higher in Group 1 with respect to Groups 2 and 3
(P < 0.05), and in Group 2 compared to Group 3 (Figs. 1–3B).
In healthy controls HLADR was found in traces, whereas
MUC5AC positivity was markedly higher compared to glau-
comatous groups (P < 0.001).
Correlations
At baseline, Spearman’s correlation analysis indicated that GCD
correlated significantly with MUC5AC positivity, whereas it
correlated negatively with HLADR positivity (P < 0.001, r ¼
0.556; P < 0.05, r ¼ 0.402). Baseline MUC5AC and GCD
correlated positively with IOP reduction (P < 0.001, r¼ 0.725;
P < 0.001, r¼ 0.641), MMD (P < 0.05; r¼ 0.325; P < 0.05, r¼
0.454), and MMA at 12 months (P < 0.001, r ¼ 0.615; P <
0.001, r ¼ 0.541). Baseline HLADR positivity correlated
negatively with 12-month IOP reduction (P < 0.001; r ¼
0.734), MMD (P < 0.05; r¼0.235), and MMA (P < 0.05; r¼
0.215). The 12-month GCD correlated positively with the IOP
reduction (P < 0.001, r¼ 0.456), MMD (P < 0.001, r¼ 0.815),
and MMA (P < 0.001, r ¼ 0.672).
DISCUSSION
Topical medications are responsible for several ocular surface
changes during medical management of glaucoma, with the
conjunctival alterations being the most critical for the surgical
outcome.20 Inflammatory cell infiltration, fibroblasts prolifera-
tion and connective deposition within the stroma, squamous
metaplasia, dendritic cell infiltration, and GC loss represent the
most common iatrogenic alterations.15,21–23 All of them may
negatively affect the AH flow through the bleb wall.11,20,21
In our study, patients with a complete surgical success
presented with higher preoperative GCD and MUC5AC
expression, compared to patients with a qualified success or
failure. This was in accordance with a previous IC study, where
higher MUC5AC and trefoil factor family (TFF) 1 (mucin-
forming peptides produced by GC) expressions were observed
in successful cases.10 Even though this study did not
specifically evaluate GC, it was hypothesized that the mucus
overexpression could result from a higher GCD. This
hypothesis also was supported by the positive correlation
between MUC5AC and TFF1 positivity. The authors proposed
that this mucin overexpression could lead to a protective
mechanism against the conjunctival aggression during medical
therapy. In failed blebs this mucin protection could be
TABLE 1. Demographics and Clinical Characteristics of Glaucomatous Groups and Controls
Group 1 Group 2 Group 3 Controls
Patients 27 12 18 15
Age, y 6 SD 64.8 6 10.16 61.7 6 8.65 63.6 6 9.88 62.4 6 6.43
Sex, M/F 14/13 7/5 9/9 8/7
Preoperative mean time of therapy, mo 6 SD 48.23 6 8.32 51.71 6 10.10 49.14 6 9.52 –
Baseline IOP, mean mm Hg 6 SD 27.2 6 3.12 27.5 6 2.23 27.7 6 1.90 14.5 6 3.90*
12-mo IOP, mean mm Hg 6 SD 15.1 6 1.79† 17.7 6 1.88† 24.1 6 1.46 15.1 6 2.75‡
Baseline N8 of drugs, mean 6 SD 3.1 6 0.41 2.9 6 0.39 3.3 6 0.47 –
12-mo N8 of drugs, mean 6 SD 0§ 1.90 6 0.48‡ 2.90 6 0.50 –
Baseline MD, mean dB 6 SD 9.21 6 3.34 8.43 6 2.22 9.89 6 4.12 1.1 6 0.4*
12-mo MD, mean dB 6 SD 9.96 6 3.02 8.12 6 1.99 10.98 6 3.81 1.3 6 0.2*
Postoperative procedures 0.9 6 0.3 1.2 6 0.7 1.9 6 0.5jj –
* P < 0.001 versus Groups 1 to 3.
† P < 0.05 versus baseline and Group 3.
‡ P < 0.05 versus Group 3.
§ P < 0.001 versus Groups 2 and 3.
jj P < 0.05 versus Groups 1 and 2.
TABLE 2. Therapy of Glaucomatous Patients
Group 1 Group 2 Group 3
PGA (9) 14.06% (5) 17.24% (7) 18.42%
PF – PGA (9) 14.06% (3) 10.34% (5) 13.15%
b-blockers (5) 6.25% (2) 6.89% (3) 7.89%
PF – b-blockers (4) 7.81% (2) 6.89% (3) 7.89%
Brimonidine (8) 12.50% (4) 13.79% (5) 13.15%
Topical CAI (14) 18.75% (5) 17.24% (6) 15.78%
Fixed combinations (17) 26.56% (8) 27.5% (9) 23.68%
P > 0.05 between Groups for all medications. PGA, prostaglandin
analogues; CAI, carbonic anhydrase inhibitors; PF, preservative-free.








Baseline 44.37 6 16.71* 29.29 6 34.80 2089.57 6 825.44
12-mo 49.11 6 12.23* 217.51 6 234.69† 17189.00 6 4182.15†
Group 2
Baseline 25.63 6 7.97 33.33 6 28.92 1932.41 6 602.79
12-mo 22.46 6 6.90‡ 95.75 6 107.07 5039.00 6 1673.85
Group 3
Baseline 22.33 6 8.38 28.88 6 27.35 1894.38 6 596.60
12-mo 18.09 6 7.14‡ 14.88 6 20.23 1917.77 6 463.13
Controls
Baseline 205.49 6 21.44§ 16.12 6 30.78jj 1621.34 6 408.18jj
12-mo 215.22 6 32.45 18.01 6 27.33 1701 6 477.20
* P < 0.05 versus Groups 2 and 3.
† P < 0.05 versus Groups 2 and 3 and controls.
‡ P < 0.05 versus baseline.
§ P < 0.001 versus Groups 1 to 3.
jj P < 0.05 versus Groups 1 to 3.
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FIGURE 1. Group 1 (Complete success). (A–D) Laser scanning conformal microscopy and IC of the conjunctiva at baseline. Laser scanning
conformal microscopy shows several GC ([A], arrowhead) and some scattered microcysts ([C], asterisk) within the epithelium; IC shows the
MUC5AC (B) and HLA-DR (D) immune staining positivity (green). Nuclei of cells were stained with propidium iodide (red). Magnification:3630. (E,
F) Laser scanning conformal microscopy of the bleb at 12 months. Goblet cells (E) did not change compared to baseline, whereas microcysts
increase their density and area (F). (G) Slit-lamp photograph. Functional filtering bleb at 12 months, with a mixed feature (diffuse/multi-cystic).
Scale bar: 50 lm.
FIGURE 2. Group 2 (Qualified success). (A–D) Laser scanning conformal microscopy and IC of the conjunctiva at baseline. Laser scanning
conformal microscopy shows a lower density of GC (A) compared to Group 1, with scattered microcysts (C) within the epithelium (arrows indicate
clusters of GC); at IC the MUC5AC (B) immune staining positivity is lower compared to Group 1, whereas HLA-DR (D) presents a similar staining.
Magnification: 3630. (E, F) Laser scanning conformal microscopy of the bleb at 12 months. Goblet cells (E) reduced with respect to baseline
(arrowheads indicate scattered GC); microcysts increased, though were much less evident compared to Group 1 (F). (G) Slit-lamp photograph.
Functional filtering bleb at 12 months, with a diffuse/encapsulated feature. Scale bar: 50 lm.
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profoundly altered and ineffective, due to a reduced GC
population. Our results confirmed the hypothesis that the
higher MUC5AC is expression of a higher GCD, since both
parameters were higher in Group 1 and positively correlated
between them.
The results of our study also supported the hypothesis of
Amar et al.,9 who supposed that GC vehiculates the AH
through the bleb-wall epithelium. In addition, based on the
role of microcysts, the 12-month positive correlation between
GCD, MMD, and MMA further support this hypothesis.
Different factors could affect the preoperative GC density,
most of them related to medical therapy. While preservatives
and b-blockers have a toxic effect, prostaglandin analogues
(PGA) positively stimulate GC.15,22–24 Thus, patients treated
with preservative-free formulations and/or PGA for longer
periods, or receiving fixed combinations, could maintain a
larger pool of GC.
In our study, the post hoc correlation between mean
number of medications and surgical outcome was not
statistically significant. However, though the difference was
not statistically significant and therapy could have changed
during the course of the disease, a slightly higher percentage of
patients was treated with preservative-free formulations or
fixed-combinations in Group 1 compared to the other groups.
On the other hand, by reviewing patient charts, it was not
possible to ascertain whether Group 1 used PGA for longer
periods, compared to Groups 2 and 3.
One also may consider that patients receiving sodium
hyaluronate-containing artificial tears to contain the iatrogenic
dry eye, could have a better behavior for GC.25 Unfortunately,
patient charts did not systematically report the use of
lubricants.
Another possible explanation is the interindividual variabil-
ity of GC: as reported, GC varies significantly between normal
subjects (338–520 cells/mm2) independently by age.18 On
these bases, one may hypothesize that patients reaching a
complete surgical success could have had a higher GCD before
initiation of medical therapy.
Positivity values for HLA-DR were consistent with the
literature, since they were markedly higher in glaucomatous
groups compared to controls, and correlated negatively with
GCD and MUC5AC production.21–24 As expected, HLA-DR did
not show significant differences between glaucomatous
groups. Despite the fact that iatrogenic inflammation strongly
reduces GC,15,21–24 the higher GCD and MUC5AC positivity in
Group 1 supported the hypothesis that differences in GCD are
not exclusively related to the conjunctival inflammation.
Nonetheless, it is not possible to rule out definitely that
Group 1 had a more preserved ocular surface. In fact, despite
the fact that HLA-DR is the most widely used biomarker to
evaluate the drug-induced conjunctival inflammation, it cannot
represent, alone, the real ocular surface status.
In line with previous reports,7,9 patients with a successful
surgery showed higher postoperative MMD and MMA values
compared to failed cases, expression of a higher AH flow
through the bleb wall. Moreover, the strong correlation
between 12-month MMD and MMA and baseline GCD and
FIGURE 3. Group 3 (Failure). (A–D) Laser scanning conformal microscopy and IC of the conjunctiva at baseline. Laser scanning conformal
microscopy shows some scattered GC (arrowhead) and epithelial microcysts (A, C). MUC5AC (B) immune staining positivity is lower compared to
Group 1 and 2 (B), whereas the HLA-DR positivity (D) is similar to Groups 1 and 2. Magnification:3630. (E, F) Laser scanning conformal microscopy
of the bleb at 12 months. GC density (E) appears further reduced with respect to baseline (arrowhead indicates a scattered GC), whereas
microcysts did not change 1 (F). (G) Slit-lamp photograph. Failed filtering bleb at 12 months, with a fibrotic and flat feature. Scale bar: 50 lm.
TABLE 4. Baseline Interobserver Agreement for GCD and MMD
GCD MMD
Investigator 1 (VF) 42.14 6 9.21 28 6 7.30




† Spearman correlation analysis.
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MUC5AC, suggested a direct active role of GC in vehiculating
the AH. This confirmed the initial results of Amar et al.9
The present study has some limitations. First, the study
cannot elucidate whether the GCD before medical therapy was
different between Groups. Thus, prospective studies following
patients from initial diagnosis are mandatory. Second, GCD was
not determined with IC, which is the gold standard method to
identify these cells, because it would have required an
additional sampling on the same site. However, previous
evidences found positive correlations between GCD measured
by LSCM and IC, even though GCD assessed by LSCM seems
higher.16,17 Further studies aimed at quantifying MUC5AC
transcripts on IC samples might significantly improve the
sensitivity of MUC5AC analysis and further confirm our
results.26 Third, GC and microcysts should be interpreted
carefully, since they may present a significant interobserver
variability. However, in the present study, GCD, MMD, and
MMA values were not significantly different between two
experienced confocal microscopy executors. Fourth, since EM
also can be found in healthy subjects and in some ocular
surface diseases, their significance should be clarified. Howev-
er, several studies indicated that in glaucoma they are a
hallmark of AH outflow.7–9,14
In closing, GC seems to have a critical role for the bleb
functionality after filtration surgery. This should be considered
strongly during the medical management of glaucoma, because
a significant proportion of patients will undergo filtration
surgery to control the damage progression. Thus, strategies
aimed at preserving GC before surgery, by reducing the ocular
surface inflammation, are recommended.
Whether these results will be confirmed in further studies,
GC could be proposed as a potential in vivo biomarker to
predict the surgical outcome and to guide clinician in
determining the appropriate time of surgery, the intraoperative
strategy, and in the postoperative bleb management.
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